Payers are stepping up efforts to manage the cost and utilization of orphan drug treatments.
Albert A. Rizzo, MD, senior medical advisor for the American Lung Association, says the increasing number of drugs in the pipeline could improve airflow and address the underlying disease process.
External, non-payer generated data can inform formulary decision-making—if payers know their strengths and weaknesses.
Recently, FDA Commissioner Scott Gottlieb announced the FDA will move to close loopholes in the Orphan Drug Program. Here’s what you need to know.
Last year was a banner year for generic drug approvals by the FDA. Find out what’s in store for 2017.
Weighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.
Our policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs.
Deaths due to opioid abuse have risen sharply—and show no signs of leveling off. Here’s how data analytics can prevent abuse and diversion.
Early planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars.
There are promising developments in the pipeline for patients with treatment-resistant depression.